Abstracts of the Second International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma ‐ New York, NY May 18–20, 2006
Identifieur interne : 000189 ( Istex/Checkpoint ); précédent : 000188; suivant : 000190Abstracts of the Second International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma ‐ New York, NY May 18–20, 2006
Auteurs :Source :
- Pediatric Blood & Cancer [ 1545-5009 ] ; 2006-06.
English descriptors
- Teeft :
- Abnormality, Acute lymphoblastic leukemia, Adult cases, Adult dlbcl, Adult patients, Aggressive lymphoma, Aichi, Aieop, Alcl, Alcl patients, Alcls, Allo, Allogeneic, Allogeneic hsct, Allosct, Anaplastic, Angelo rosolen, Anna hospital, Api2, Api2 moiety, Apoptosis, Arcadia, Arup, Assay, Autohsct, Autologous, Autosct, Azienda, Bcl2, Bone marrow, Bone marrow involvement, Brigid bradley, Burkitt, Burkitt lymphoma, Carmella, Case report, Cdna, Cell lines, Cell lymphoma, Cell lymphomas, Cell transplantation, Chemotherapy, Child health, Childhood lymphoblastic lymphoma, Childhood lymphoma, Childhood lymphomas, Chimeric, Chimerism, Chromosomal, Chromosome, Clin, Clinical characteristics, Clinical data, Clinical features, Clinical presentation, Cohort, Columbia university, Comparative analysis, Complete remission, Constitutive, Cranial, Cranial irradiation, Cranial radiotherapy, Ctcl, Ctls, Cutaneous, Cutaneous lymphoma, Cyclophosphamide, Cytarabine, Cytogenetic, Cytokine, Cytotoxic, Cytotoxicity, Database, Deletion, Diagnosis, Disease progression, Dlbcl, Dos, Dosing, Doxorubicin, Early relapse, Ebna1, Embolism, Enfermedades, Enfermedades neoplasicas, Engraftment, Epidemiology, Epitope, Erin, Erin cooney, Etoposide, Evaluable, Excellent outcome, Extranodal, Extranodal lymphoma, Follicular lymphoma, Gene, Gene expression, Genetics, Genomic, Giessen, Gvhd, Gvhd prophylaxis, Haematology, Hdmtx, Hematologic, Hematological, Hematology, Hematopoietic, High risk, Histologic, Histological, Histology, Hodgkin, Hodgkin disease, Hodgkin lymphoma, Hodgkin lymphomas, Hpsct, Hsct, Hybridization, Immune, Immune response, Immunohistochemical, Immunohistochemistry, Immunology, Immunotherapy, Induction phase, Inen, Instituto, Instituto nacional, Intrathecal, Invasive, Jacls, Jacls trial, James garvin, January, June, Karen wolownik, Karyotype, Kiel, Kinase, Kinetics, Kingdom cancer study group, Kurume, Lara, Lara mussolin, Leukaemia, Leukemia, Leukemic, Lima, Luigi zanesco, Lymph, Lymph nodes, Lymphoblastic, Lymphoblastic lymphoma, Lymphoblastic lymphomas, Lymphocyte, Lymphoid, Lymphoid malignancies, Lymphoma, Lymphoma cells, Lymphoproliferative, Lysis, Maintenance therapy, Malignancy, Malignant, Marrow, Marta, Marta pillon, Median, Median time, Mediastinal, Mediastinum, Medical university, Methotrexate, Microarray, Militano, Modality, Moiety, Monoclonal, Monoclonal antibodies, Morbidity, Mucositis, Multicenter, Murphy stage, Mussolin, Mutation, Mycosis fungoides, Nacional, Nagoya, Ndings, Neck region, Neoplasicas, Neoplasm, Nkg2d, Node, Nonhodgkin, Notch1, Olga militano, Oligonucleotide, Oncogene, Oncogenic, Oncologia pediatrica, Oncology, Oncology group, Ongoing, Other sites, Overall survival, Overexpression, Padova, Paediatric, Partial remission, Pathogenesis, Pathway, Patte, Paulo, Pbsc, Pbsct, Pediatr, Pediatr blood cancer, Pediatric, Pediatric cases, Pediatric dlbcl, Pediatric germany, Pediatric hematology, Pediatric lymphomas, Pediatric patients, Pediatric university hospital, Pediatrica, Pediatrics, Pediatrique, Pefs, Peripheral blood, Peripheral lymphoma, Pharm, Phenotype, Pillon, Pmlbl, Poor prognosis, Prakash, Prakash satwani, Precursor, Preliminary results, Pres, Primary cutaneous, Primary mediastinal, Primary site, Prognosis, Prognostic, Prognostic factors, Prognostic value, Progression, Progressive disease, Prophylactic, Prophylaxis, Proteomic, Protocol, Psychological domain, Ptcl, Ptld, Radiation therapy, Radiotherapy, Randomized, Range years, Rasburicase, Rearrangement, Receptor, Refractory, Refractory disease, Regimen, Reinduction, Reiter, Relapse, Remission, Renal, Residual, Response kinetics, Retrospective, Retrospective analysis, Rituximab, Rosolen, Salt lake city, Satwani, Secondary aberrations, Serum levels, Sfop, Sherrie, Societe francaise pediatrique, Subset, Subtypes, Survival rate, Svegf, Systemic disease, Taas, Tetsuya, Therapy, Thrombotic, Thrombotic embolism, Toro, Toxic death, Toxicity, Transcriptional, Translocation, Transplantation, Treatment outcome, Treatment results, Treatment strategy, Tumor cells, Tumour, Ukccsg, University hospital, Utah health sciences center, Vegf, Vincristine, Vocal cord paralysis, York presbyterian hospital, Young adults.
Url:
DOI: 10.1002/pbc.20869
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:1875D38016A23914925D570EE8F8FB4FB098F62DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Abstracts of the Second International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma ‐ New York, NY May 18–20, 2006</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1875D38016A23914925D570EE8F8FB4FB098F62D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/pbc.20869</idno>
<idno type="url">https://api.istex.fr/document/1875D38016A23914925D570EE8F8FB4FB098F62D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001050</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001050</idno>
<idno type="wicri:Area/Istex/Curation">001049</idno>
<idno type="wicri:Area/Istex/Checkpoint">000189</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000189</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Abstracts of the Second International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma ‐ New York, NY May 18–20, 2006</title>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Pediatric Blood & Cancer</title>
<title level="j" type="alt">PEDIATRIC BLOOD AND CANCER</title>
<idno type="ISSN">1545-5009</idno>
<idno type="eISSN">1545-5017</idno>
<imprint><biblScope unit="vol">46</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="834">834</biblScope>
<biblScope unit="page" to="878">878</biblScope>
<biblScope unit="page-count">45</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-06">2006-06</date>
</imprint>
<idno type="ISSN">1545-5009</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1545-5009</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term>
<term>Acute lymphoblastic leukemia</term>
<term>Adult cases</term>
<term>Adult dlbcl</term>
<term>Adult patients</term>
<term>Aggressive lymphoma</term>
<term>Aichi</term>
<term>Aieop</term>
<term>Alcl</term>
<term>Alcl patients</term>
<term>Alcls</term>
<term>Allo</term>
<term>Allogeneic</term>
<term>Allogeneic hsct</term>
<term>Allosct</term>
<term>Anaplastic</term>
<term>Angelo rosolen</term>
<term>Anna hospital</term>
<term>Api2</term>
<term>Api2 moiety</term>
<term>Apoptosis</term>
<term>Arcadia</term>
<term>Arup</term>
<term>Assay</term>
<term>Autohsct</term>
<term>Autologous</term>
<term>Autosct</term>
<term>Azienda</term>
<term>Bcl2</term>
<term>Bone marrow</term>
<term>Bone marrow involvement</term>
<term>Brigid bradley</term>
<term>Burkitt</term>
<term>Burkitt lymphoma</term>
<term>Carmella</term>
<term>Case report</term>
<term>Cdna</term>
<term>Cell lines</term>
<term>Cell lymphoma</term>
<term>Cell lymphomas</term>
<term>Cell transplantation</term>
<term>Chemotherapy</term>
<term>Child health</term>
<term>Childhood lymphoblastic lymphoma</term>
<term>Childhood lymphoma</term>
<term>Childhood lymphomas</term>
<term>Chimeric</term>
<term>Chimerism</term>
<term>Chromosomal</term>
<term>Chromosome</term>
<term>Clin</term>
<term>Clinical characteristics</term>
<term>Clinical data</term>
<term>Clinical features</term>
<term>Clinical presentation</term>
<term>Cohort</term>
<term>Columbia university</term>
<term>Comparative analysis</term>
<term>Complete remission</term>
<term>Constitutive</term>
<term>Cranial</term>
<term>Cranial irradiation</term>
<term>Cranial radiotherapy</term>
<term>Ctcl</term>
<term>Ctls</term>
<term>Cutaneous</term>
<term>Cutaneous lymphoma</term>
<term>Cyclophosphamide</term>
<term>Cytarabine</term>
<term>Cytogenetic</term>
<term>Cytokine</term>
<term>Cytotoxic</term>
<term>Cytotoxicity</term>
<term>Database</term>
<term>Deletion</term>
<term>Diagnosis</term>
<term>Disease progression</term>
<term>Dlbcl</term>
<term>Dos</term>
<term>Dosing</term>
<term>Doxorubicin</term>
<term>Early relapse</term>
<term>Ebna1</term>
<term>Embolism</term>
<term>Enfermedades</term>
<term>Enfermedades neoplasicas</term>
<term>Engraftment</term>
<term>Epidemiology</term>
<term>Epitope</term>
<term>Erin</term>
<term>Erin cooney</term>
<term>Etoposide</term>
<term>Evaluable</term>
<term>Excellent outcome</term>
<term>Extranodal</term>
<term>Extranodal lymphoma</term>
<term>Follicular lymphoma</term>
<term>Gene</term>
<term>Gene expression</term>
<term>Genetics</term>
<term>Genomic</term>
<term>Giessen</term>
<term>Gvhd</term>
<term>Gvhd prophylaxis</term>
<term>Haematology</term>
<term>Hdmtx</term>
<term>Hematologic</term>
<term>Hematological</term>
<term>Hematology</term>
<term>Hematopoietic</term>
<term>High risk</term>
<term>Histologic</term>
<term>Histological</term>
<term>Histology</term>
<term>Hodgkin</term>
<term>Hodgkin disease</term>
<term>Hodgkin lymphoma</term>
<term>Hodgkin lymphomas</term>
<term>Hpsct</term>
<term>Hsct</term>
<term>Hybridization</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immunohistochemical</term>
<term>Immunohistochemistry</term>
<term>Immunology</term>
<term>Immunotherapy</term>
<term>Induction phase</term>
<term>Inen</term>
<term>Instituto</term>
<term>Instituto nacional</term>
<term>Intrathecal</term>
<term>Invasive</term>
<term>Jacls</term>
<term>Jacls trial</term>
<term>James garvin</term>
<term>January</term>
<term>June</term>
<term>Karen wolownik</term>
<term>Karyotype</term>
<term>Kiel</term>
<term>Kinase</term>
<term>Kinetics</term>
<term>Kingdom cancer study group</term>
<term>Kurume</term>
<term>Lara</term>
<term>Lara mussolin</term>
<term>Leukaemia</term>
<term>Leukemia</term>
<term>Leukemic</term>
<term>Lima</term>
<term>Luigi zanesco</term>
<term>Lymph</term>
<term>Lymph nodes</term>
<term>Lymphoblastic</term>
<term>Lymphoblastic lymphoma</term>
<term>Lymphoblastic lymphomas</term>
<term>Lymphocyte</term>
<term>Lymphoid</term>
<term>Lymphoid malignancies</term>
<term>Lymphoma</term>
<term>Lymphoma cells</term>
<term>Lymphoproliferative</term>
<term>Lysis</term>
<term>Maintenance therapy</term>
<term>Malignancy</term>
<term>Malignant</term>
<term>Marrow</term>
<term>Marta</term>
<term>Marta pillon</term>
<term>Median</term>
<term>Median time</term>
<term>Mediastinal</term>
<term>Mediastinum</term>
<term>Medical university</term>
<term>Methotrexate</term>
<term>Microarray</term>
<term>Militano</term>
<term>Modality</term>
<term>Moiety</term>
<term>Monoclonal</term>
<term>Monoclonal antibodies</term>
<term>Morbidity</term>
<term>Mucositis</term>
<term>Multicenter</term>
<term>Murphy stage</term>
<term>Mussolin</term>
<term>Mutation</term>
<term>Mycosis fungoides</term>
<term>Nacional</term>
<term>Nagoya</term>
<term>Ndings</term>
<term>Neck region</term>
<term>Neoplasicas</term>
<term>Neoplasm</term>
<term>Nkg2d</term>
<term>Node</term>
<term>Nonhodgkin</term>
<term>Notch1</term>
<term>Olga militano</term>
<term>Oligonucleotide</term>
<term>Oncogene</term>
<term>Oncogenic</term>
<term>Oncologia pediatrica</term>
<term>Oncology</term>
<term>Oncology group</term>
<term>Ongoing</term>
<term>Other sites</term>
<term>Overall survival</term>
<term>Overexpression</term>
<term>Padova</term>
<term>Paediatric</term>
<term>Partial remission</term>
<term>Pathogenesis</term>
<term>Pathway</term>
<term>Patte</term>
<term>Paulo</term>
<term>Pbsc</term>
<term>Pbsct</term>
<term>Pediatr</term>
<term>Pediatr blood cancer</term>
<term>Pediatric</term>
<term>Pediatric cases</term>
<term>Pediatric dlbcl</term>
<term>Pediatric germany</term>
<term>Pediatric hematology</term>
<term>Pediatric lymphomas</term>
<term>Pediatric patients</term>
<term>Pediatric university hospital</term>
<term>Pediatrica</term>
<term>Pediatrics</term>
<term>Pediatrique</term>
<term>Pefs</term>
<term>Peripheral blood</term>
<term>Peripheral lymphoma</term>
<term>Pharm</term>
<term>Phenotype</term>
<term>Pillon</term>
<term>Pmlbl</term>
<term>Poor prognosis</term>
<term>Prakash</term>
<term>Prakash satwani</term>
<term>Precursor</term>
<term>Preliminary results</term>
<term>Pres</term>
<term>Primary cutaneous</term>
<term>Primary mediastinal</term>
<term>Primary site</term>
<term>Prognosis</term>
<term>Prognostic</term>
<term>Prognostic factors</term>
<term>Prognostic value</term>
<term>Progression</term>
<term>Progressive disease</term>
<term>Prophylactic</term>
<term>Prophylaxis</term>
<term>Proteomic</term>
<term>Protocol</term>
<term>Psychological domain</term>
<term>Ptcl</term>
<term>Ptld</term>
<term>Radiation therapy</term>
<term>Radiotherapy</term>
<term>Randomized</term>
<term>Range years</term>
<term>Rasburicase</term>
<term>Rearrangement</term>
<term>Receptor</term>
<term>Refractory</term>
<term>Refractory disease</term>
<term>Regimen</term>
<term>Reinduction</term>
<term>Reiter</term>
<term>Relapse</term>
<term>Remission</term>
<term>Renal</term>
<term>Residual</term>
<term>Response kinetics</term>
<term>Retrospective</term>
<term>Retrospective analysis</term>
<term>Rituximab</term>
<term>Rosolen</term>
<term>Salt lake city</term>
<term>Satwani</term>
<term>Secondary aberrations</term>
<term>Serum levels</term>
<term>Sfop</term>
<term>Sherrie</term>
<term>Societe francaise pediatrique</term>
<term>Subset</term>
<term>Subtypes</term>
<term>Survival rate</term>
<term>Svegf</term>
<term>Systemic disease</term>
<term>Taas</term>
<term>Tetsuya</term>
<term>Therapy</term>
<term>Thrombotic</term>
<term>Thrombotic embolism</term>
<term>Toro</term>
<term>Toxic death</term>
<term>Toxicity</term>
<term>Transcriptional</term>
<term>Translocation</term>
<term>Transplantation</term>
<term>Treatment outcome</term>
<term>Treatment results</term>
<term>Treatment strategy</term>
<term>Tumor cells</term>
<term>Tumour</term>
<term>Ukccsg</term>
<term>University hospital</term>
<term>Utah health sciences center</term>
<term>Vegf</term>
<term>Vincristine</term>
<term>Vocal cord paralysis</term>
<term>York presbyterian hospital</term>
<term>Young adults</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000189 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000189 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Psychologie |area= BernheimV1 |flux= Istex |étape= Checkpoint |type= RBID |clé= ISTEX:1875D38016A23914925D570EE8F8FB4FB098F62D |texte= Abstracts of the Second International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma ‐ New York, NY May 18–20, 2006 }}
This area was generated with Dilib version V0.6.33. |